Animal Biosafety Level: Protecting Life, Ensuring Safety

Marcin Frankowski^*
*Correspondence: Marcin Frankowski, Department of Animal Psychology and Health Sciences, University College Cork, Cork, Ireland, Email:

Description

Animal Biosafety Levels (ABSL) play a critical role in safeguarding both human and animal health. They are designed to mitigate the risks associated with handling and working with animals, particularly those carrying infectious agents that can potentially pose a threat to human populations or other animals. By implementing stringent biosafety measures, we can protect the well-being of both animals and the individuals involved in their care. Animal biosafety levels are a framework that categorizes the risk associated with handling specific animals and their associated pathogens. The levels range from ABSL-1 to ABSL-4, with each level representing a progressively higher level of containment and safety precautions.

ABSL-1 is the lowest level, applicable to animals that pose minimal risk to human and animal health. Typically, animals at this level do not carry infectious agents that cause severe disease in healthy individuals. Basic personal protective equipment (PPE) such as gloves and lab coats are often sufficient for working with animals at this level. Moving up the scale, ABSL-2 applies to animals that may carry potentially harmful agents but do not pose a significant threat to healthy individuals. At this level, additional safety precautions such as enhanced PPE, biosafety cabinets, and restricted access areas are implemented to minimize the risk of exposure. ABSL-3 represents a moderate to high-risk level, involving animals that carry infectious agents capable of causing severe diseases in humans or animals [1]. The containment measures at this level include dedicated animal facilities, controlled airflow systems, and strict adherence to comprehensive biosafety protocols. Finally, ABSL-4 is the highest level, reserved for animals hosting highly contagious and deadly pathogens that lack effective treatments or vaccines. Handling animals at this level requires specialized facilities equipped with advanced containment systems, including airlocks, fullbody personal protective suits, and rigorous decontamination procedures.

The implementation of animal biosafety levels is vital for several reasons. First and foremost, they protect human health. By categorizing animals based on their potential risks, biosafety levels ensure that appropriate measures are taken to minimize the transmission of infectious agents to humans [2]. This is crucial in preventing zoonotic diseases, which are illnesses that can be transmitted from animals to humans, such as avian influenza or Ebola. Animal biosafety levels also safeguard animal health and welfare. By following strict containment protocols, we can prevent the introduction and spread of diseases within animal populations. This is especially important in settings such as veterinary clinics, research laboratories, or animal production facilities, where animals from different sources are often brought together, increasing the risk of disease transmission.

Furthermore, ABSLs are essential for the protection of researchers, animal caretakers, and anyone involved in working with animals. These individuals face potential exposure to infectious agents, which can have serious health consequences. By providing guidelines and standard operating procedures, biosafety levels ensure that appropriate precautions are taken to safeguard their well-being [3]. The adoption of animal biosafety levels also contributes to global biosecurity efforts. In an interconnected world, where travel and trade are widespread, infectious diseases can rapidly spread across borders. Implementing biosafety measures helps prevent the accidental release or escape of pathogens, reducing the likelihood of outbreaks and minimizing their impact on public health and economies. Additionally, the on-going COVID-19 pandemic has highlighted the importance of biosafety measures and the need for preparedness in the face of emerging infectious diseases. This experience has sparked discussions on strengthening ABSL programs, enhancing global surveillance, and improving response capabilities [4]. It has also emphasized the importance of interdisciplinary collaboration between human health, animal health, and environmental sectors to address complex health challenges effectively.

In conclusion, the discussion surrounding Animal Biosafety Levels (ABSL) is multifaceted and touches upon various aspects, including risk assessment, facility design, training, cost, international collaboration, and future developments. ABSL programs play a crucial role in protecting life and ensuring safety when working with animals carrying infectious agents [5]. By implementing appropriate containment measures based on risk assessment, we can minimize the potential for disease transmission, safeguard human and animal health, and contribute to global biosecurity efforts. Continued discussions, research, and collaboration are vital to address challenges, share knowledge, and advance biosafety practices in an evolving world.

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Sun, Xiaoming, Zhuang Liu, Kevin Welsher and Joshua Tucker Robinson, et al "Nano-graphene oxide for cellular imaging and drug delivery." Nano Res 1 (2008): 203-212.

Google Scholar, Crossref, Indexed at

2. Mahmoudi, Morteza, Hossein Hosseinkhani, Mohsen Hosseinkhani and Sebastien Boutry, et al. "Magnetic resonance imaging tracking of stem cells in vivo using iron oxide nanoparticles as a tool for the advancement of clinical regenerative medicine." Chem Rev 111 (2011): 253-280.

Google Scholar, Crossref, Indexed at

3. Kiser, M. A., Paul Westerhoff, T. Benn and Y. Wang, et al. "Titanium nanomaterial removal and release from wastewater treatment plants." Environ Sci Technol 43 (2009): 6757-6763.

Google Scholar, Crossref, Indexed at

4. Kägi, Ralf, Andrea Ulrich, Brian Sinnet and Roger Vonbank, et al. "Synthetic TiO2 nanoparticle emission from exterior facades into the aquatic environment." Environ Pollut 156 (2008): 233-239.

Google Scholar, Crossref, Indexed at

5. Russell, Stephen J., John C. Bell, Christine E. Engeland and Grant McFadden, et al. "Advances in oncolytic virotherapy." Commun Med 2 (2022): 33.

Google Scholar, Crossref, Indexed at